Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Beginning Cash Balance: 2021-2025

Historic Beginning Cash Balance for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $11.1 million.

  • InMed Pharmaceuticals' Beginning Cash Balance rose 69.59% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 16.12%. This contributed to the annual value of $6.6 million for FY2025, which is 26.27% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Beginning Cash Balance stood at $11.1 million, which was up 138.15% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Beginning Cash Balance ranged from a high of $15.3 million in Q4 2021 and a low of $3.4 million during Q1 2025.
  • Over the past 3 years, InMed Pharmaceuticals' median Beginning Cash Balance value was $7.6 million (recorded in 2024), while the average stood at $7.8 million.
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Beginning Cash Balance was 69.59% (2025), while the steepest drop was 63.93% (2025).
  • InMed Pharmaceuticals' Beginning Cash Balance (Quarterly) stood at $15.3 million in 2021, then crashed by 39.06% to $9.4 million in 2022, then fell by 27.94% to $6.7 million in 2023, then declined by 15.95% to $5.7 million in 2024, then skyrocketed by 69.59% to $11.1 million in 2025.
  • Its Beginning Cash Balance was $11.1 million in Q3 2025, compared to $4.7 million in Q2 2025 and $3.4 million in Q1 2025.